Feedback / Questions
margetuximab (MGAH 22) - MacroGenics
Margetuximab: Second interim OS data from P3 SOPHIA trial (NCT02492711) in HER2+ metastatic breast cancer at SABCS (Dec 10- 14, 2019)
(Macrogenics)
-
Nov 9, 2019 -
Corporate Presentation
P3 data
http://ir.macrogenics.com/static-files/c73fd3d3-6a17-4f04-95d9-3d6c39eb7411
Nov 9, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious